EXEL vs. VRTX
Compare and contrast key facts about Exelixis, Inc. (EXEL) and Vertex Pharmaceuticals Incorporated (VRTX).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: EXEL or VRTX.
Key characteristics
| EXEL | VRTX | |
|---|---|---|
| YTD Return | 46.10% | 18.94% |
| 1Y Return | 65.10% | 38.54% |
| 3Y Return (Ann) | 24.79% | 37.45% |
| 5Y Return (Ann) | 16.29% | 18.24% |
| 10Y Return (Ann) | 34.95% | 15.84% |
| Sharpe Ratio | 2.06 | 1.24 |
| Sortino Ratio | 3.20 | 1.99 |
| Omega Ratio | 1.42 | 1.26 |
| Calmar Ratio | 1.08 | 2.58 |
| Martin Ratio | 9.21 | 5.63 |
| Ulcer Index | 6.95% | 5.47% |
| Daily Std Dev | 31.15% | 24.79% |
| Max Drawdown | -97.38% | -91.77% |
| Current Drawdown | -28.83% | -6.34% |
Fundamentals
| EXEL | VRTX | |
|---|---|---|
| Market Cap | $10.24B | $126.19B |
| EPS | $1.55 | -$1.91 |
| PEG Ratio | 2.63 | 1.32 |
| Total Revenue (TTM) | $2.02B | $10.61B |
| Gross Profit (TTM) | $1.94B | $9.14B |
| EBITDA (TTM) | $609.58M | -$147.50M |
Correlation
The correlation between EXEL and VRTX is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
EXEL vs. VRTX - Performance Comparison
In the year-to-date period, EXEL achieves a 46.10% return, which is significantly higher than VRTX's 18.94% return. Over the past 10 years, EXEL has outperformed VRTX with an annualized return of 34.95%, while VRTX has yielded a comparatively lower 15.84% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
EXEL vs. VRTX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
EXEL vs. VRTX - Dividend Comparison
Neither EXEL nor VRTX has paid dividends to shareholders.
Drawdowns
EXEL vs. VRTX - Drawdown Comparison
The maximum EXEL drawdown since its inception was -97.38%, which is greater than VRTX's maximum drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for EXEL and VRTX. For additional features, visit the drawdowns tool.
Volatility
EXEL vs. VRTX - Volatility Comparison
Exelixis, Inc. (EXEL) has a higher volatility of 13.41% compared to Vertex Pharmaceuticals Incorporated (VRTX) at 9.57%. This indicates that EXEL's price experiences larger fluctuations and is considered to be riskier than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
EXEL vs. VRTX - Financials Comparison
This section allows you to compare key financial metrics between Exelixis, Inc. and Vertex Pharmaceuticals Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities